Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy

Head and Neck Cancer Clinical Trial

Official title:

An Open-label, International, Multi-Center, Phase I/II, Dose-escalation Trial Investigating the Safety of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Combination With Radiotherapy, in Patients With Stage III, IVa or IVb Locally Advanced Squamous Cell Carcinoma of the Head and Neck Ineligible for Platinum Based Chemotherapy

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00707655
• Other study ID #: GEN207
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: September 2008
• Est. completion date: October 2010

Study information

• Verified date: August 2023
• Source: Genmab
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate the safety of zalutumumab in combination with radiotherapy as the treatment of patients with head and neck cancer who are not eligible for platinum based chemotherapy.

Description:

This is an open label, multi-center, phase I/II dose-escalation clinical trial investigating the safety of zalutumumab in combination with radiotherapy. The safety of zalutumumab doses in combination with radiotherapy (RT) will be investigated using 3 patient cohorts in a dose-escalation / de-escalation design based on Dose Limiting Toxicity (DLT). The dose-escalation starts at 8 mg/kg zalutumumab in combination with RT. Initially, three patients will be treated at a dose level and observed for DLTs. If none of the three patients experience a DLT, then the next cohort of three patients is treated at the next higher dose of zalutumumab. If one of three patients treated at a dose level experience a DLT, then three more patients are treated at the same dose level. If two or more of the three patients experience DLTs, then the next cohort of three patients should be treated at the next lower dose of zalutumumab, unless at least six patients on that dose have already been dosed. Furthermore, if 1 or fewer DLTs are observed among six patients at a given dose level, then the next cohort of three patients is treated at the next higher dose of zalutumumab. The maximum tolerated dose will be decided by Genmab based on the recommendations made by the IDMC on the basis of their review of the aggregated safety data.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 8
• Est. completion date: October 2010
• Est. primary completion date: October 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients with histologically or cytologically confirmed diagnosis of locally advanced squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx stage III, IVa or IVb

2. Measurable disease defined as one or more target lesions according to RECIST based onCT scan or MRI and clinical evaluation

3. Eligible for intended curative radiotherapy

4. Patients considered ineligible for platinum based chemotherapy based on investigator's judgment

5. Age > 18 years

6. Following receipt of verbal and written information about the study, the patient must provide signed informed consent before any study related activity is carried out

Exclusion Criteria:

1. Prior radiotherapy to the head and neck area

2. Prior chemotherapy administered for cancer in the head and neck area

3. Prior targeted therapy (e.g. EGFR antibodies or EGFR inhibitors)

4. Received the following treatments within 4 weeks prior to Visit 2:

1. Retinoic acid

2. Other immunosuppressive drugs (e.g. drugs interfering with the functions of T cells, IL-2 or equivalent)

3. Any non-marketed drug substance

5. Past or current malignancy other than SCCHN, except for:

• Cervical carcinoma Stage 1B or less

• Non-invasive basal cell skin carcinoma

• Squamous cell skin carcinoma

• Stage 1 or 2 treated prostate cancer with PSA in the normal range for >2 years post treatment

• Malignant melanoma with a complete response duration of > 10 years

• Other cancer diagnoses with a complete response duration of > 5 years

6. Metastatic SCCHN disease

7. Chronic or current infectious disease such as, but not limited to, chronic renal infection and tuberculosis

8. Clinically significant cardiac disease including unstable angina, acute myocardial infarction within six months before Visit 1, congestive heart failure, and arrhythmia requiring anti-arrhythmic therapy, with the exception of extra systoles or minor conduction abnormalities

9. Significant concurrent, uncontrolled medical condition including, but not limited to,hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease considered to preclude trial treatment and/or compliance according to the Investigator's opinion, or any other condition preventing therapy according to the Investigator's opinion

10. Known HIV positive

11. Known active hepatitis B and/or hepatitis C

12. Screening laboratory values:

• Neutrophils < 1.5 x 109/L

• Platelets < 100 x109/L

• Hemoglobin < 6 mmol/L

13. Current participation in any other interventional clinical study

14. Patients known or suspected of not being able to comply with a study protocol (e.g. due to alcoholism, drug dependency, or psychological disorder)

15. Known or suspected hypersensitivity to components of the investigational medicinal Product

16. Breast feeding women or women with a positive pregnancy test at screening blood Sample

17. Males not willing to use adequate contraception during study and for 12 months after last dose of zalutumumab or women of childbearing potential not willing to use adequate contraception as hormonal birth control or intrauterine device during study and for 12 months after last dose of zalutumumab

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Head and Neck Cancer
• Head and Neck Neoplasms
• Squamous Cell Carcinoma

Intervention

Drug:
• Zalutumumab
Eight weekly infusions

Locations

Country	Name	City	State
Belgium	St-Luc University Hospital	Brussels
France	Centre Georges-Francois Leclerc Hospital	Dijon
France	Medical Oncology, Outpatient Clinic	Nantes
France	Institut Claudius Regaud Toulouse	Toulouse
United Kingdom	St James's Institute of Oncology	Leeds
United Kingdom	The Royal Marsden NHS Foundation Trust	London
United Kingdom	Christie Hospital NHS Foundation Trust	Manchester
United Kingdom	Sheffield Teaching Hospitals NHS Foundation Trust	Sheffield

Sponsors (1)

Lead Sponsor	Collaborator
Genmab

Countries where clinical trial is conducted

Belgium,  France,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Adverse Events (AEs)	Number of participants with at least one adverse event. All adverse events are collected during 12 weeks and all serious adverse events are collected during 2 years.	From first dose date up to end of the safety follow up period (Up to 2 years)
Secondary	Number of Participants With Best Overall Tumour Response	The Best Overall Tumour Response defined as the best response recorded from the start of treatment until disease progression or recurrence per RECIST criteria. Complete response (CR) defined as the disappearance of all target lesions. Partial response (PR) defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. Progressive disease (PD) defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started, or the appearance of one or more new lesions since the prior scan. Stable disease (SD) defined as responses not fulfilling CR, PR or PD.	Up to 2 years
Secondary	Number of Participants With Objective Response	Objective response is defined as CR or PR according to RECIST criteria. CR is defined as the disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter.	Up to 2 years